Paclitaxel (Synonyms:紫杉醇)
目录号 : KM18910 CAS No. : 33069-62-4 纯度 : 98%

Paclitaxel 是一种天然抗肿瘤药,可稳定微管蛋白 (tubulin) 的聚合。Paclitaxel 可导致有丝分裂停滞和诱导细胞凋亡 (apoptosis),最终导致细胞死亡。Paclitaxel 还可诱导细胞自噬 (autophagy)。

规格 价格 是否有货 数量
10mg
In-stock
50mg
In-stock
100mg
In-stock
500mg
In-stock
1g 询价 In-stock
5g 询价 In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

Paclitaxel is a naturally occurring antineoplastic agent and stabilizes tubulin polymerization. Paclitaxel can cause both mitotic arrest and apoptotic cell death. Paclitaxel also induces autophagy.

体外研究

Paclitaxel (20 nM; 48 hours) induces programmed cell death and exists a block at the G2/M phase of the cell cycle.
Paclitaxel (20 nM; 48 hours) induces a consistent increase in the level of p53.

Apoptosis Analysis

Cell Line: MCF-7, MDA-MB-231 cells
Concentration: 20 nM
Incubation Time: 48 hours
Result: Induced programmed cell death.

Cell Cycle Analysis

Cell Line: MCF-7, MDA-MB-231 cells
Concentration: 20 nM
Incubation Time: 48 hours
Result: >60% of MCF-7 cells and 50% of MDA-MB-231 cells were in the G2/M phase following 24 h treament.

Western Blot Analysis

Cell Line: MCF-7 cells (harboring wild-type p53)
Concentration: 20 nM
Incubation Time: 48 hours
Result: Induced a consistent increase in the level of p53.
体内研究

Paclitaxel (1-20 mg/kg; i.p.; 1 time/2 days for five cycles) obviously induces liver metastases at the low-Paclitaxel group with little influence on primary tumor growth.

Animal Model: MDA-231 xenograft-bearing mice
Dosage: 1, 20 mg/kg
Administration: Intraperitoneal injection; five cycles (1 time/2 days)
Result: Liver metastases were obviously induced in the low-PTX (1 mg/kg) group with little influence on primary tumor growth compared with high-PTX group.
分子式
C47H51NO14
分子量
853.91
CAS号
33069-62-4
中文名称
紫杉醇
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL (117.11 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1711 mL 5.8554 mL 11.7108 mL
5 mM 0.2342 mL 1.1711 mL 2.3422 mL
10 mM 0.1171 mL 0.5855 mL 1.1711 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.44 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.08 mg/mL (2.44 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.08 mg/mL (2.44 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.08 mg/mL (2.44 mM); Clear solution

    此方案可获得 ≥ 2.08 mg/mL (2.44 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

临床试验
科研文献
暂无相关参考文献
The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2